The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02, FiscalAI reports. Altimmune plans to seek an FDA end-of-Phase II meeting for AUD and believes a single global Phase III trial could satisfy U.S. and European requirements. Altimmune plans to seek an FDA end-of-Phase II meeting for AUD and believes a single global Phase III trial could satisfy U.S. and European requirements. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Altimmune in a report on Wednesday, June 24th. HC Wainwright reiterated a “buy” rating on shares of Altimmune in a research note on Tuesday, July 28th.